BACKGROUND & AIMS:RM-131, a synthetic ghrelin agonist, greatly accelerates gastric emptying of solids in patients with type 2 diabetes and delayed gastric emptying (DGE). We investigated the safety and effects of a single dose of RM-131 on gastric emptying and upper gastrointestinal (GI) symptoms in patients with type 1 diabetes and previously documented DGE. METHODS: In a double-blind cross-over study, 10 patients with type 1 diabetes (age, 45.7 ± 4.4 y; body mass index, 24.1 ± 1.1 kg/m(2)) and previously documented DGE were assigned in random order to receive a single dose of RM-131 (100 μg, subcutaneously) or placebo. Thirty minutes later, they ate a radiolabeled solid-liquid meal containing EggBeaters (ConAgra Foods, Omaha, NE), and then underwent 4 hours of gastric emptying and 6 hours of colonic filling analyses by scintigraphy. Upper GI symptoms were assessed using a daily diary, gastroparesis cardinal symptom index (total GCSI-DD) and a combination of nausea, vomiting, fullness, and pain (NVFP) scores (each rated on a 0-5 scale). RESULTS: At screening, participants' mean level of hemoglobin A1c was 9.1% ± 0.5%; their total GCSI-DD score was 1.66 ± 0.38 (median, 1.71), and their total NVFP score was 1.73 ± 0.39 (median, 1.9). The t1/2 of solid gastric emptying was 84.9 ± 31.6 minutes when subjects were given RM-131 and 118.7 ± 26.7 when they were given a placebo. The median difference (Δ)was 33.9 minutes (interquartile range [IQR] -12, -49), or -54.7% (IQR, -21%,-110%). RM-131 decreased gastric retention of solids at 1 hour (P = .005) and 2 hours (P = .019). Numeric differences in t1/2 for gastric emptying of liquids, solid gastric emptying lag time, and colonic filling at 6 hours were not significant. Total GCSI-DD scores were 0.79 on placebo (IQR, 0.75, 2.08) and 0.17 on RM-131 (IQR, 0.00, 0.67; P = .026); NVFP scores were lower on RM-131 (P = .041). There were no significant adverse effects. CONCLUSIONS:RM-131 significantly accelerates gastric emptying of solids and reduces upper GI symptoms in patients with type 1 diabetes and documented DGE.
RCT Entities:
BACKGROUND & AIMS:RM-131, a synthetic ghrelin agonist, greatly accelerates gastric emptying of solids in patients with type 2 diabetes and delayed gastric emptying (DGE). We investigated the safety and effects of a single dose of RM-131 on gastric emptying and upper gastrointestinal (GI) symptoms in patients with type 1 diabetes and previously documented DGE. METHODS: In a double-blind cross-over study, 10 patients with type 1 diabetes (age, 45.7 ± 4.4 y; body mass index, 24.1 ± 1.1 kg/m(2)) and previously documented DGE were assigned in random order to receive a single dose of RM-131 (100 μg, subcutaneously) or placebo. Thirty minutes later, they ate a radiolabeled solid-liquid meal containing EggBeaters (ConAgra Foods, Omaha, NE), and then underwent 4 hours of gastric emptying and 6 hours of colonic filling analyses by scintigraphy. Upper GI symptoms were assessed using a daily diary, gastroparesis cardinal symptom index (total GCSI-DD) and a combination of nausea, vomiting, fullness, and pain (NVFP) scores (each rated on a 0-5 scale). RESULTS: At screening, participants' mean level of hemoglobin A1c was 9.1% ± 0.5%; their total GCSI-DD score was 1.66 ± 0.38 (median, 1.71), and their total NVFP score was 1.73 ± 0.39 (median, 1.9). The t1/2 of solid gastric emptying was 84.9 ± 31.6 minutes when subjects were given RM-131 and 118.7 ± 26.7 when they were given a placebo. The median difference (Δ)was 33.9 minutes (interquartile range [IQR] -12, -49), or -54.7% (IQR, -21%,-110%). RM-131 decreased gastric retention of solids at 1 hour (P = .005) and 2 hours (P = .019). Numeric differences in t1/2 for gastric emptying of liquids, solid gastric emptying lag time, and colonic filling at 6 hours were not significant. Total GCSI-DD scores were 0.79 on placebo (IQR, 0.75, 2.08) and 0.17 on RM-131 (IQR, 0.00, 0.67; P = .026); NVFP scores were lower on RM-131 (P = .041). There were no significant adverse effects. CONCLUSIONS:RM-131 significantly accelerates gastric emptying of solids and reduces upper GI symptoms in patients with type 1 diabetes and documented DGE.
Keywords:
AE; CF6; CRU; Clinical Research Unit; Clinical Trial; DGE; Drug; GCSI-DD; GE; GI; Gastroparesis; IQR; NVFP; Prokinetic; T1DM; T2DM; adverse event; colonic filling at 6 hours; daily diary of gastroparesis cardinal symptom index; delayed gastric emptying; gastric emptying; gastrointestinal; interquartile range; nausea, vomiting fullness, pain; t(1/2); the calculated time point at which 50% of the radiolabeled meal has emptied from the stomach; type 1 diabetes mellitus; type 2 diabetes mellitus
Authors: C D R Murray; N M Martin; M Patterson; S A Taylor; M A Ghatei; M A Kamm; C Johnston; S R Bloom; A V Emmanuel Journal: Gut Date: 2005-08-05 Impact factor: 23.059
Authors: J Tack; I Depoortere; R Bisschops; C Delporte; B Coulie; A Meulemans; J Janssens; T Peeters Journal: Gut Date: 2005-10-10 Impact factor: 23.059
Authors: G Tougas; E Y Eaker; T L Abell; H Abrahamsson; M Boivin; J Chen; M P Hocking; E M Quigley; K L Koch; A Z Tokayer; V Stanghellini; Y Chen; J D Huizinga; J Rydén; I Bourgeois; R W McCallum Journal: Am J Gastroenterol Date: 2000-06 Impact factor: 10.864
Authors: Maria I Vazquez Roque; Michael Camilleri; Debra A Stephens; Michael D Jensen; Duane D Burton; Kari L Baxter; Alan R Zinsmeister Journal: Gastroenterology Date: 2006-10-15 Impact factor: 22.682
Authors: N Ejskjaer; E T Vestergaard; P M Hellström; L C Gormsen; S Madsbad; J L Madsen; T A Jensen; J C Pezzullo; J S Christiansen; L Shaughnessy; G Kosutic Journal: Aliment Pharmacol Ther Date: 2009-02-27 Impact factor: 8.171
Authors: G J Sanger; S M Westaway; A A Barnes; D T Macpherson; A I Muir; E M Jarvie; V N Bolton; S Cellek; E Näslund; P M Hellström; R A Borman; W P Unsworth; K L Matthews; K Lee Journal: Neurogastroenterol Motil Date: 2009-06 Impact factor: 3.598
Authors: Hye-Kyung Jung; Rok Seon Choung; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; Lawrence A Szarka; Brian Mullan; Nicholas J Talley Journal: Gastroenterology Date: 2008-12-24 Impact factor: 22.682
Authors: Subhankar Chakraborty; Magnus Halland; Duane Burton; Anshuman Desai; Bridget Neja; Phillip Low; Wolfgang Singer; Michael Camilleri; Alan R Zinsmeister; Adil E Bharucha Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958